Golden Years Home Care Reaffirms Commitment to Specialized Alzheimer's Home Care for Lincoln, CA, Families
Golden Years Home Care reaffirms its dedication to providing specialized Alzheimer's home care for seniors in Lincoln, CA. Their trained dementia caregivers deliver compassionate, person-centered support, helping clients age safely at home while easing the burden on family caregivers. Services include managing symptoms, creating structured routines, and fostering comfort, dignity, and emotional well-being for both seniors and their loved ones.
Lincoln, CA - Golden Years Home Care today announced its continued prioritization of specialized in-home care services for individuals and families affected by Alzheimer's disease. This renewed focus reinforces the organization's commitment to the Lincoln community by ensuring that seniors facing the challenges of dementia have access to expert and compassionate support within the comfort and familiarity of their own homes.
An Alzheimer's diagnosis presents unique and evolving challenges for both the individual and their family. As the condition progresses, the need for specialized care that addresses cognitive changes, safety concerns, and emotional well-being becomes paramount. Golden Years Home Care recognizes the significant strain this can place on family caregivers. It aims to provide a reliable, professional solution that promotes a higher quality of life for everyone involved.
One of the primary benefits of this specialized service is the ability for seniors to age in place safely and with dignity. The consistent presence of a familiar caregiver in a known environment helps reduce confusion and anxiety, which are common symptoms of Alzheimer's. The agency's dedicated Alzheimer caregivers in Lincoln, CA, are specifically trained in dementia care protocols, including effective communication techniques, managing behavioral symptoms, and creating structured routines that provide comfort and security for the client.
Furthermore, the service provides invaluable support and respite for family members. Entrusting the care of a loved one to a professional allows family caregivers to tend to their health, careers, and personal lives without guilt or worry. This support system helps prevent caregiver burnout and allows families to shift their focus from being full-time caregivers to spending more quality time as sons, daughters, and spouses, strengthening their emotional connection with their loved one.
"Families navigating an Alzheimer's diagnosis deserve a partner they can trust," stated Ken Ballard, owner of Golden Years Home Care. "Our goal has always been to provide more than just assistance; we provide understanding and specialized support. Our program for Alzheimer's Home Care in Lincoln, CA, is built on a foundation of compassion, ensuring every senior can live with dignity and comfort in the place they know best."
Golden Years Home Care is dedicated to creating personalized care plans tailored to the specific needs and stage of each client's condition. By focusing on person-centered care, the agency ensures that seniors with Alzheimer's in Lincoln receive the respect, compassion, and expert attention they rightfully deserve.
For more information about Golden Years Home Care and their Alzheimer's Home Care in Lincoln, CA, please visit their website at https://goldenyearshomecare.com/roseville-ca
About Golden Years Home Care:
Golden Years Home Care is a premier provider of in-home senior care services based in Lincoln, CA. Specializing in memory care, companion care, and personal assistance, the agency is committed to enhancing the quality of life for seniors and their families through compassionate, reliable, and professional support.
Media Contact
Company Name: Golden Years Home Care (Roseville, CA)
Contact Person: Ken Ballard
Email: Send Email
Phone: (916) 665-4355
Address: 420 FOLSOM RD # A-10
City: Roseville
State: California 95678-2767
Country: United States
Website: https://goldenyearshomecare.com/roseville-ca/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
21 minutes ago
- National Post
Curewell Capital Closes Oversubscribed Inaugural Fund at $535 Million
Article content LOS ANGELES — Curewell Capital ('Curewell'), a private equity firm focused on building industry-leading middle-market healthcare companies, announced the closing of Curewell Capital I, LP (together with its related vehicles, the 'Fund') at its hard cap of $535 million. The inaugural Fund was raised in a single closing and completed less than five months after launch. Article content Curewell secured commitments from a diverse group of global institutional investors, comprised of leading endowments, foundations, pensions, insurance companies, consultants, family offices, and industry executives. Article content Curewell is led by Michael Dal Bello and Ceron Rhee, who have worked together for nearly two decades, including their shared tenures at Blackstone and more recently at Pritzker Private Capital, where they led the healthcare investment practice. The Fund builds on the team's established strategy of acquiring leading U.S. healthcare businesses across healthcare services, pharmaceutical services, medical devices, and healthcare technology. Curewell seeks to partner with experienced founders and management teams leading extraordinary healthcare companies to help accelerate growth and operational performance. Article content 'We are grateful for the trust and support of an exceptional group of investors. We are further honored to work with founders, owners, and management teams who share our vision of increasing access to healthcare, lowering overall system costs, and enhancing quality of care. We look forward to building lasting value together,' said Michael Dal Bello, Co-Founder and Partner. 'This fund represents our next chapter in partnering with accomplished teams advancing innovation and transformation in healthcare,' added Ceron Rhee, Co-Founder and Partner. 'We are seeing strong secular tailwinds across our key areas of focus, providing meaningful opportunities for companies to improve outcomes and drive efficiencies throughout the U.S. healthcare system.' Article content Probitas Partners acted as the exclusive placement advisor for the Fund, and Kirkland & Ellis LLP acted as fund counsel. Article content About Curewell Capital Article content Curewell is a Los Angeles–based private equity firm focused on building industry-leading middle-market healthcare companies headquartered in North America. Drawing upon decades of investment and operating experience across healthcare services, pharmaceutical services, medical devices, and healthcare technology, Curewell seeks to partner with founders and management teams leading premier companies that improve patient outcomes, create efficiencies, and foster innovation. Curewell's proprietary GRO™ framework is tailored to each company to drive long-term value through growth and operational excellence. For additional information, please visit Article content Article content Article content Article content
Globe and Mail
an hour ago
- Globe and Mail
Wellness Eternal Releases July 2025 Biohacking Index Report: Verified Top-Rated Companies Leading the Future of Wellness
Wellness Eternal Launches First-Ever Biohacking Index Report Monthly rankings establish third-party verification standard for wellness industry Valhalla, New York--(Newsfile Corp. - August 20, 2025) - Wellness Eternal today announced the release of the July 2025 Biohacking Index Report, the first in a monthly series ranking wellness and longevity companies based on verified reviews from doctors, clinic owners, health professionals, customers, and patients. The July 2025 Biohacking Index highlights a fiercely competitive field with multiple companies securing perfect 5.0 ratings, showcasing the rising standards and excellence in the biohacking industry. To view an enhanced version of this graphic, please visit: The Biohacking Index is a third-party verified platform that evaluates companies based on verified reviews from healthcare professionals and customers. Only Premium Members are eligible to be officially indexed and included in the monthly reports. July 2025 Report Results The July 2025 report features eleven companies with ratings between 4.8 and 5.0, with eight receiving perfect 5.0 scores based on verified reviews from healthcare professionals and customers. The companies achieving perfect 5.0 scores include companies across diverse segments from diagnostics to therapeutic devices. The full report, available at includes detailed company profiles, locations, ratings, and review sources. "This is more than a ranking-it's a verified record of what's actually working in the wellness world," said Lindsay O'Neill, founder of Wellness Eternal and the Biohacking Index. "By combining verified consumer feedback with practitioner input, we're establishing a verification standard for transparency in biohacking." The timing of this launch reflects growth in the wellness industry, with biohacking representing an expanding market segment. Expanding Industry Impact and Future Focus As a contributor to established media publications, O'Neill distributes data from the Biohacking Index Monthly Report to over 300 news media outlets, as well as directly to investors, wellness buyers, and practitioners seeking reliable market intelligence. Starting in August 2025, each report will focus on a specific category, beginning with Red Light Therapy, followed by PEMF & Vibration, HBOT (Hyperbaric Oxygen Therapy), Detox & Lymphatic Health, and Diagnostics. This category-specific approach will provide deeper market insights and help establish performance benchmarks within specialized wellness sectors. About Wellness Eternal and the Biohacking Index Founded by biohacking expert Lindsay O'Neill, Wellness Eternal is dedicated to advancing transparency and accountability in the wellness industry. The Biohacking Index is a ratings and reviews platform for biohacking, longevity, and wellness companies. The platform provides information to help consumers and practitioners make informed decisions.
Globe and Mail
an hour ago
- Globe and Mail
Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025
ALAMEDA, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) ('Vivani' or the 'Company'), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, announced today that CEO Adam Mendelsohn, Ph.D., will present a company overview and conduct partnering meetings at the H.C. Wainwright 27th Annual Global Investment Conference, taking place from September 8-10, 2025 in New York, New York. Details of Dr. Mendelsohn's presentation are as follows: Date: Wednesday, September 10, 2025 Time: 1:00 PM - 1:30 pm, Eastern Time Location: Lotte New York Palace Hotel, Holmes I - 4th Floor Dr. Mendelsohn will highlight Vivani's portfolio of miniature, ultra long-acting drug implants, powered by its proprietary NanoPortal™ drug implant technology. These innovative implants are designed to address poor medication adherence and improve patient outcomes in chronic disease management. The Company is prioritizing the advancement of NPM-139, a novel semaglutide implant, with clinical development expected to begin in 2026, pending regulatory clearance. More information about the H.C. Wainwright 27th Annual Global Investment Conference can be found at About Vivani Medical, Inc. Leveraging its proprietary NanoPortal™ platform, Vivani develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time with the goal of guaranteeing adherence and improving patient tolerance to their medication. Today, medication non-adherence affects approximately 50% of patients. Vivani's priority product candidate, NPM-139, is a miniature, six-month, subdermal, GLP-1 (semaglutide) implant under development for chronic weight management in obese or overweight subjects. NPM-139 has the added potential for once-yearly dosing. Vivani's emerging pipeline also includes NPM-115 (exenatide implant) for chronic weight management in obese and overweight individuals, and NPM-119, an exenatide implant program for the treatment of type-2 diabetes. These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability and loss of efficacy. Forward-Looking Statements This press release contains certain 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'target,' 'believe,' 'expect,' 'will,' 'may,' 'anticipate,' 'estimate,' 'would,' 'positioned,' 'future,' and other similar expressions that in this press release, including statements regarding Vivani's business, products in development, including the therapeutic potential thereof, the planned development therefor, the completion of the LIBERATE-1 Phase 1 study and reporting of study results, Vivani's emerging development plans for NPM-139, NPM-115, NPM-119 or Vivani's plans with respect its technology, strategy, cash position and financial runway. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on Vivani's current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Vivani's control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause actual results and outcomes to differ materially from those indicated in the forward-looking statements include, among others, risks related to the development and commercialization of Vivani's products, including NPM-139, NPM-115, and NPM-119; delays and changes in the development of Vivani's products, including as a result of applicable laws, regulations and guidelines, potential delays in submitting and receiving regulatory clearance or approval to conduct Vivani's development activities, including Vivani's ability to commence clinical development of NPM-139; risks related to the initiation, enrollment and conduct of Vivani's planned clinical studies and the results therefrom; or Vivani's history of losses and Vivani's ability to access additional capital or otherwise fund Vivani's business. There may be additional risks that the Company considers immaterial, or which are unknown. A further list and description of risks and uncertainties can be found in the Company's most recent Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission on March 31, 2025, as updated by the Company's subsequent Quarterly Reports on Form 10-Q. Any forward-looking statement made by Vivani in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of added information, future developments or otherwise, except as required by law. Company Contact: Donald Dwyer Chief Business Officer info@ (415) 506-8462 Investor Relations Contact: Jami Taylor Investor Relations Advisor investors@ (415) 506-8462 Media Contact: Mark Corbae ICR Healthcare (203) 682-8288
